CR20140395A - Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina - Google Patents
Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilaminaInfo
- Publication number
- CR20140395A CR20140395A CR20140395A CR20140395A CR20140395A CR 20140395 A CR20140395 A CR 20140395A CR 20140395 A CR20140395 A CR 20140395A CR 20140395 A CR20140395 A CR 20140395A CR 20140395 A CR20140395 A CR 20140395A
- Authority
- CR
- Costa Rica
- Prior art keywords
- processes
- preparation
- metansulfoniletilamine
- metoxifenil
- etoxi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se proveen nuevos procesos para la preparación de intermediarios de aminosulfona para la síntesis de 2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfonil-etil]-4-acetilaminoisoindolino-1,3-diona, que es útil para prevenir o tratar enfermedades o condiciones relacionadas con un nivel o actividad anormalmente alto de TNF-?. Además, en el presente documento se proveen procesos para la producción comercial de (S)-1-(3-etoxi-4-metoxifenil)-2-metansulfonil-etilamina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261601226P | 2012-02-21 | 2012-02-21 | |
PCT/US2013/026780 WO2013126360A2 (en) | 2012-02-21 | 2013-02-20 | Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140395A true CR20140395A (es) | 2014-11-17 |
Family
ID=47755073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20140395A CR20140395A (es) | 2012-02-21 | 2014-08-21 | Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina |
Country Status (36)
Country | Link |
---|---|
US (3) | US9187417B2 (es) |
EP (4) | EP3312156B1 (es) |
JP (1) | JP2015509496A (es) |
KR (1) | KR101993248B1 (es) |
CN (3) | CN112812044B (es) |
AR (2) | AR090100A1 (es) |
AU (1) | AU2013203283B2 (es) |
BR (3) | BR112014020444B1 (es) |
CA (1) | CA2864517A1 (es) |
CO (1) | CO7061071A2 (es) |
CR (1) | CR20140395A (es) |
CY (2) | CY1121833T1 (es) |
DK (2) | DK3312156T3 (es) |
ES (4) | ES2773686T3 (es) |
HK (1) | HK1205501A1 (es) |
HR (2) | HRP20191249T1 (es) |
HU (2) | HUE048412T2 (es) |
IL (3) | IL234135A (es) |
IN (1) | IN2014DN06740A (es) |
LT (2) | LT3312156T (es) |
MX (2) | MX350731B (es) |
MY (1) | MY168296A (es) |
NI (1) | NI201400093A (es) |
NZ (1) | NZ628028A (es) |
PH (1) | PH12014501865B1 (es) |
PL (2) | PL3378850T3 (es) |
PT (2) | PT3378850T (es) |
RS (2) | RS60036B1 (es) |
RU (1) | RU2632875C2 (es) |
SG (1) | SG11201405035XA (es) |
SI (2) | SI3378850T1 (es) |
TR (1) | TR201910430T4 (es) |
TW (1) | TW201336815A (es) |
UA (1) | UA116773C2 (es) |
WO (1) | WO2013126360A2 (es) |
ZA (1) | ZA201405892B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126906B2 (en) * | 2012-02-21 | 2015-09-08 | Celgene Corporation | Asymmetric synthetic processes for the preparation of aminosulfone compounds |
AR090100A1 (es) | 2012-02-21 | 2014-10-22 | Celgene Corp | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
NZ628329A (en) | 2013-06-17 | 2017-12-22 | Celgene Corp | Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
IN2014MU01283A (es) | 2014-04-04 | 2015-10-09 | Cadila Healthcare Ltd | |
US9994522B2 (en) | 2014-05-11 | 2018-06-12 | Mapi Pharma Ltd. | Amorphous form of apremilast |
EP2949645A1 (en) | 2014-05-28 | 2015-12-02 | LEK Pharmaceuticals d.d. | Processes for the preparation of ß-aminosulfone compounds |
CN105622380B (zh) * | 2014-10-29 | 2020-06-30 | 南京安源生物医药科技有限公司 | 一种阿普斯特的制备方法及其中间体 |
CN104447445B (zh) * | 2014-12-05 | 2016-07-06 | 新发药业有限公司 | 一种合成阿普斯特中间体的制备方法 |
CN104761474B (zh) * | 2015-03-11 | 2016-11-30 | 中山奕安泰医药科技有限公司 | 一种阿普斯特手性胺中间体的合成方法 |
CN104744323B (zh) * | 2015-03-11 | 2016-08-31 | 中山奕安泰医药科技有限公司 | 一种阿普斯特手性胺中间体的合成工艺 |
CN104803897A (zh) * | 2015-04-23 | 2015-07-29 | 中山奕安泰医药科技有限公司 | 一种阿普斯特中间体的合成工艺 |
US10370329B2 (en) * | 2015-04-27 | 2019-08-06 | Mylan Laboratories Limited | Process for the enantiomeric resolution of apremilast intermediates |
US20180334429A1 (en) * | 2015-06-09 | 2018-11-22 | Dr. Reddy's Laboratories Limited | Process for preparation of apremilast and its intermediates |
EP3106457A1 (en) | 2015-06-15 | 2016-12-21 | LEK Pharmaceuticals d.d. | A novel synthetic pathway towards apremilast |
EP3144393A1 (en) * | 2015-09-18 | 2017-03-22 | LEK Pharmaceuticals d.d. | A synthetic pathway towards apremilast |
WO2017059040A1 (en) | 2015-09-29 | 2017-04-06 | Pliva Hrvatska D.O.O. | Processes for the preparation of apremilast and intermediates thereof |
US10399942B2 (en) | 2015-11-19 | 2019-09-03 | Alembic Pharmaceuticals Limited | Process and novel polymorphic form of Apremilast |
CN105330586B (zh) * | 2015-11-27 | 2017-12-22 | 东华大学 | 一种阿普斯特的制备方法 |
CN105461602B (zh) * | 2015-11-27 | 2018-01-02 | 东华大学 | 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法 |
WO2017094031A2 (en) * | 2015-12-04 | 2017-06-08 | Sun Pharmaceutical Industries Limited | Novel process for preparation of apremilast |
CN106866475B (zh) * | 2015-12-11 | 2018-03-30 | 北大方正集团有限公司 | 一种阿普斯特中间体及其制备方法 |
WO2017179065A1 (en) | 2016-04-15 | 2017-10-19 | Davuluri Ramamohan Rao | Improved process for the preparation of apremilast |
US10196355B2 (en) | 2016-06-20 | 2019-02-05 | Johnson Matthey Public Limited Company | Forms of apremilast |
CN106543050B (zh) * | 2016-09-28 | 2018-04-10 | 中南大学湘雅医院 | 一种阿普斯特中间体的合成工艺 |
WO2018061034A1 (en) * | 2016-09-30 | 2018-04-05 | Sun Pharmaceutical Industries Limited | Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine |
JP6684968B2 (ja) | 2016-11-10 | 2020-04-22 | エス・エム・エス・グループ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 連続鋳造圧延設備内において、金属的なストリップを製造するための方法 |
CN107445875A (zh) * | 2017-03-22 | 2017-12-08 | 陕西科技大学 | 一种用于制备阿普斯特的高纯度中间体的手性拆分方法 |
EP3606907B1 (en) | 2017-04-04 | 2021-01-20 | Quimica Sintetica, S.A. | Racemic beta-aminosulfone compounds |
ES2829253T3 (es) | 2017-04-04 | 2021-05-31 | Quim Sintetica S A | Resolución de compuestos de beta-aminosulfona racémicos |
CN107827722B (zh) * | 2017-11-23 | 2021-02-19 | 中山奕安泰医药科技有限公司 | 一种3-乙氧基-4-甲氧基苯甲醛的合成方法 |
CN107976501B (zh) * | 2017-11-23 | 2020-08-25 | 中山奕安泰医药科技有限公司 | 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法 |
CN107941945B (zh) * | 2017-11-23 | 2020-12-22 | 中山奕安泰医药科技有限公司 | 一种3-乙氧基-4-甲氧基苯甲腈的检测方法 |
CN107966509B (zh) * | 2017-11-23 | 2020-06-23 | 中山奕安泰医药科技有限公司 | 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法 |
CN108008035B (zh) * | 2017-11-23 | 2020-07-07 | 中山奕安泰医药科技有限公司 | 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法 |
CN108084066A (zh) * | 2017-12-12 | 2018-05-29 | 中山大学 | 一种阿普斯特及对映异构体的合成方法 |
JP6673614B1 (ja) * | 2018-10-16 | 2020-03-25 | 東芝エレベータ株式会社 | 防音装置 |
CN113896674B (zh) * | 2021-09-01 | 2023-10-27 | 深圳华中科技大学研究院 | 一种阿普斯特的合成方法 |
CN115850129B (zh) * | 2023-02-28 | 2023-05-16 | 凯莱英生命科学技术(天津)有限公司 | (s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙胺的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1261455A (en) * | 1969-03-06 | 1972-01-26 | Burroughs Wellcome Co | Improvements in or relating to substituted acrylonitriles |
US3878252A (en) * | 1970-09-24 | 1975-04-15 | Burroughs Wellcome Co | Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide |
DE2051871A1 (en) * | 1969-05-16 | 1971-11-18 | The Wellcome Foundation Ltd., London | Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents |
NZ331875A (en) | 1996-03-22 | 2000-01-28 | Du Pont Pharm Co | Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
DE60330187D1 (de) | 2002-12-30 | 2009-12-31 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
US7208526B2 (en) | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
CA2711576C (en) * | 2008-01-25 | 2016-06-21 | High Point Pharmaceuticals, Llc | Tricyclic compounds as inhibitors of tnf-.alpha. synthesis and as pde4 inhibitors |
SI2334639T1 (sl) | 2008-09-10 | 2013-06-28 | Celgene Corporation | Procesi za pripravo spojin aminosulfonov |
AU2010260249B2 (en) * | 2009-06-18 | 2013-09-05 | Concert Pharmaceuticals, Inc. | Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors |
US8415485B2 (en) | 2009-10-09 | 2013-04-09 | Celgene Corporation | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds |
WO2012097116A2 (en) | 2011-01-14 | 2012-07-19 | Celgene Corporation | Isotopologues of isoindole derivatives |
US9126906B2 (en) * | 2012-02-21 | 2015-09-08 | Celgene Corporation | Asymmetric synthetic processes for the preparation of aminosulfone compounds |
AR090100A1 (es) * | 2012-02-21 | 2014-10-22 | Celgene Corp | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
-
2013
- 2013-02-19 AR ARP130100512A patent/AR090100A1/es active IP Right Grant
- 2013-02-20 RS RS20200185A patent/RS60036B1/sr unknown
- 2013-02-20 EP EP17197504.8A patent/EP3312156B1/en active Active
- 2013-02-20 HU HUE18168969A patent/HUE048412T2/hu unknown
- 2013-02-20 TR TR2019/10430T patent/TR201910430T4/tr unknown
- 2013-02-20 ES ES18168969T patent/ES2773686T3/es active Active
- 2013-02-20 MY MYPI2014702288A patent/MY168296A/en unknown
- 2013-02-20 BR BR112014020444-6A patent/BR112014020444B1/pt active IP Right Grant
- 2013-02-20 JP JP2014558783A patent/JP2015509496A/ja active Pending
- 2013-02-20 PT PT181689696T patent/PT3378850T/pt unknown
- 2013-02-20 EP EP20150560.9A patent/EP3702347B1/en active Active
- 2013-02-20 HU HUE17197504 patent/HUE044192T2/hu unknown
- 2013-02-20 PL PL18168969T patent/PL3378850T3/pl unknown
- 2013-02-20 UA UAA201410289A patent/UA116773C2/uk unknown
- 2013-02-20 EP EP18168969.6A patent/EP3378850B8/en active Active
- 2013-02-20 PT PT17197504T patent/PT3312156T/pt unknown
- 2013-02-20 RU RU2014138037A patent/RU2632875C2/ru active
- 2013-02-20 SI SI201331685T patent/SI3378850T1/sl unknown
- 2013-02-20 AU AU2013203283A patent/AU2013203283B2/en active Active
- 2013-02-20 BR BR122021020040-8A patent/BR122021020040B1/pt active IP Right Grant
- 2013-02-20 ES ES13706898.7T patent/ES2675168T3/es active Active
- 2013-02-20 WO PCT/US2013/026780 patent/WO2013126360A2/en active Application Filing
- 2013-02-20 BR BR122021020046-7A patent/BR122021020046B1/pt active IP Right Grant
- 2013-02-20 CN CN202110092737.0A patent/CN112812044B/zh active Active
- 2013-02-20 LT LTEP17197504.8T patent/LT3312156T/lt unknown
- 2013-02-20 MX MX2016016157A patent/MX350731B/es unknown
- 2013-02-20 KR KR1020147026186A patent/KR101993248B1/ko active IP Right Grant
- 2013-02-20 ES ES17197504T patent/ES2735801T3/es active Active
- 2013-02-20 EP EP13706898.7A patent/EP2817288B1/en active Active
- 2013-02-20 SI SI201331526T patent/SI3312156T1/sl unknown
- 2013-02-20 RS RS20190895A patent/RS59071B1/sr unknown
- 2013-02-20 CN CN201710255841.0A patent/CN107033042A/zh active Pending
- 2013-02-20 SG SG11201405035XA patent/SG11201405035XA/en unknown
- 2013-02-20 IN IN6740DEN2014 patent/IN2014DN06740A/en unknown
- 2013-02-20 DK DK17197504.8T patent/DK3312156T3/da active
- 2013-02-20 CN CN201380020005.4A patent/CN104245668B/zh active Active
- 2013-02-20 DK DK18168969.6T patent/DK3378850T3/da active
- 2013-02-20 MX MX2014010002A patent/MX344190B/es active IP Right Grant
- 2013-02-20 ES ES20150560T patent/ES2971710T3/es active Active
- 2013-02-20 NZ NZ628028A patent/NZ628028A/en unknown
- 2013-02-20 CA CA2864517A patent/CA2864517A1/en not_active Withdrawn
- 2013-02-20 LT LTEP18168969.6T patent/LT3378850T/lt unknown
- 2013-02-20 US US13/771,164 patent/US9187417B2/en active Active
- 2013-02-20 TW TW102105901A patent/TW201336815A/zh unknown
- 2013-02-20 PL PL17197504T patent/PL3312156T3/pl unknown
-
2014
- 2014-08-12 ZA ZA2014/05892A patent/ZA201405892B/en unknown
- 2014-08-14 IL IL234135A patent/IL234135A/en active IP Right Grant
- 2014-08-18 PH PH12014501865A patent/PH12014501865B1/en unknown
- 2014-08-20 NI NI201400093A patent/NI201400093A/es unknown
- 2014-08-21 CR CR20140395A patent/CR20140395A/es unknown
- 2014-08-21 CO CO14183628A patent/CO7061071A2/es unknown
-
2015
- 2015-06-25 HK HK15106059.8A patent/HK1205501A1/xx unknown
- 2015-10-14 US US14/882,564 patent/US9586897B2/en active Active
-
2017
- 2017-01-25 US US15/414,782 patent/US9688623B2/en active Active
- 2017-05-23 IL IL252459A patent/IL252459B/en active IP Right Grant
-
2019
- 2019-07-11 CY CY20191100742T patent/CY1121833T1/el unknown
- 2019-07-12 HR HRP20191249TT patent/HRP20191249T1/hr unknown
-
2020
- 2020-01-10 AR ARP200100066A patent/AR117963A2/es unknown
- 2020-02-13 HR HRP20200245TT patent/HRP20200245T1/hr unknown
- 2020-02-21 CY CY20201100163T patent/CY1122799T1/el unknown
- 2020-03-04 IL IL273050A patent/IL273050A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20140395A (es) | Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina | |
UY34216A (es) | Nuevos compuestos que inhiben la actividad de la Lp-PLA2 | |
GT201400034A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
UY34445A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
DOP2017000013A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
GT201300258A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
DOP2012000238A (es) | Compuestos de para la inhibición de inmunoproteasomas | |
MX358128B (es) | Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos. | |
CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
UY33627A (es) | Compuestos para tratar enfermedades neurodegenerativas | |
CR20130550A (es) | Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina | |
ECSP14013236A (es) | Polimorfos de inhibidores de cinasas | |
ECSP088961A (es) | Nuevos herbicidas | |
UY34336A (es) | Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina | |
UY34742A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
UY34108A (es) | ?proceso para la fabricación de sustratos revestidos?. | |
CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
CR20130106A (es) | Nuevos moduladores de trpv3 | |
CL2013000310A1 (es) | Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades. | |
DOP2012000260A (es) | Uso de nuevos inhibidores de pancdk para tratar tumores | |
UY34612A (es) | ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?. | |
UY34277A (es) | Metodo para la eliminación del naftaleno |